J Cancer
2023; 14(8):1335.
doi:10.7150/jca.85747 This issueCite
Retraction
PART1 expression is associated with poor prognosis and tumor recurrence in stage I-III non-small cell lung cancer: Retraction
Ming Li1,*, Weiwei Zhang2,*, Shenjun Zhang3, Changhui Wang1, Yinping Lin1,3,✉
1. Department of Respiratory Medicine, Shanghai 10th People's Hospital, Tongji University, Shanghai 200072, China. 2. Department of Endocrinology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200092, China 3. Institute of Biochemistry and Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China. *These authors have contributed equally to this work.
✉ Corresponding author
Citation:
Li M, Zhang W, Zhang S, Wang C, Lin Y. PART1 expression is associated with poor prognosis and tumor recurrence in stage I-III non-small cell lung cancer: Retraction. J Cancer 2023; 14(8):1335. doi:10.7150/jca.85747. https://www.jcancer.org/v14p1335.htm
Li, M., Zhang, W., Zhang, S., Wang, C., Lin, Y. (2023). PART1 expression is associated with poor prognosis and tumor recurrence in stage I-III non-small cell lung cancer: Retraction. Journal of Cancer, 14(8), 1335. https://doi.org/10.7150/jca.85747.
ACS
Li, M.; Zhang, W.; Zhang, S.; Wang, C.; Lin, Y. PART1 expression is associated with poor prognosis and tumor recurrence in stage I-III non-small cell lung cancer: Retraction. J. Cancer 2023, 14 (8), 1335. DOI: 10.7150/jca.85747.
NLM
Li M, Zhang W, Zhang S, Wang C, Lin Y. PART1 expression is associated with poor prognosis and tumor recurrence in stage I-III non-small cell lung cancer: Retraction. J Cancer 2023; 14(8):1335. doi:10.7150/jca.85747. https://www.jcancer.org/v14p1335.htm
CSE
Li M, Zhang W, Zhang S, Wang C, Lin Y. 2023. PART1 expression is associated with poor prognosis and tumor recurrence in stage I-III non-small cell lung cancer: Retraction. J Cancer. 14(8):1335.
This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.